Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00326053 |
The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: Budesonide/formoterol |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse |
Estimated Enrollment: | 600 |
Study Start Date: | May 2006 |
Study Completion Date: | May 2007 |
Primary Completion Date: | May 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada | |
Research Site | |
Quebec, Canada | |
Canada, Alberta | |
Research Site | |
Edmonton, Alberta, Canada | |
Research Site | |
St. Albert, Alberta, Canada | |
Research Site | |
Calgary, Alberta, Canada | |
Research Site | |
Lethbridge, Alberta, Canada | |
Canada, British Columbia | |
Research Site | |
Nanaimo, British Columbia, Canada | |
Research Site | |
Vancouver, British Columbia, Canada | |
Canada, Nova Scotia | |
Research Site | |
Halifax, Nova Scotia, Canada | |
Research Site | |
Truro, Nova Scotia, Canada | |
Canada, Ontario | |
Research Site | |
Toronto, Ontario, Canada | |
Research Site | |
Ottawa, Ontario, Canada | |
Research Site | |
Kingston, Ontario, Canada | |
Research Site | |
Hamilton, Ontario, Canada | |
Research Site | |
Niagara Falls, Ontario, Canada | |
Research Site | |
Thunder Bay, Ontario, Canada | |
Canada, Prince Edward Island | |
Research Site | |
Charlottetown, Prince Edward Island, Canada | |
Canada, Quebec | |
Research Site | |
Montreal, Quebec, Canada | |
Research Site | |
La Malbaie, Quebec, Canada | |
Research Site | |
Ste-Foy, Quebec, Canada | |
Canada, Saskatchewan | |
Research Site | |
Saskatoon, Saskatchewan, Canada |
Study Director: | Gloria Jordana, MD | AstraZeneca |
Principal Investigator: | Brian Rowe, MD | University of Alberta |
Study ID Numbers: | D5890L00017, PARADE |
Study First Received: | May 12, 2006 |
Last Updated: | January 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00326053 |
Health Authority: | Canada: Health Canada |
Asthma Reoccurrence Acute Asthma Patient Discharge |
Emergency Service, Hospital Asthma Exacerbation Asthma Relapse |
Symbicort Budesonide Asthma Recurrence Terbutaline Lung Diseases, Obstructive Hypersensitivity |
Respiratory Tract Diseases Lung Diseases Hypersensitivity, Immediate Emergencies Formoterol Respiratory Hypersensitivity |
Anti-Inflammatory Agents Respiratory System Agents Neurotransmitter Agents Disease Attributes Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic beta-Agonists Bronchial Diseases Immune System Diseases Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists |
Anti-Asthmatic Agents Hormones Glucocorticoids Adrenergic Agonists Pharmacologic Actions Pathologic Processes Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Bronchodilator Agents |